Docetaxel 80 mg IV 1 vial Turkey

testimony

• Mammary cancer. Taxotere ® in combination with doxorubicin and cyclophosphamide is intended for adjuvant therapy in patients with:
• resectable breast cancer with lymph node involvement
• resectable breast cancer without lymph node involvement.
• In patients with operable breast cancer without lymph node involvement, adjuvant therapy should be performed if patients are eligible for chemotherapy in accordance with internationally accepted criteria for primary treatment of early-stage breast cancer.
• Taxotere ® in combination with doxorubicin is intended for the treatment of patients with locally or metastatic breast cancer who have not previously received cytotoxic therapy for this disease.
• Taxotere ® as monotherapy is indicated for the treatment of patients with locally or metastatic breast cancer after failure of cytotoxic therapy, which included an anthracycline or an alkyluval drug.
• Taxotere ® in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer with increased expression of HER-2 by tumor cells who have not previously received chemotherapy for metastases.
• Taxotere ® in combination with capecitabine is indicated for the treatment of patients with locally or metastatic breast cancer who have failed anthracycline therapy.
• Non-small cell lung cancer. Taxotere ® is indicated for the treatment of patients with locally or metastatic non-small cell lung cancer after chemotherapy failure.
• Taxotere ® in combination with cisplatin is indicated for the treatment of patients with unresectable, locally or metastatic non-small cell lung cancer, if previous chemotherapy for this condition has not been performed.
• Prostate cancer Taxotere ® in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
• Adenocarcinoma of the stomach. Taxotere ® in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including gastroesophageal adenocarcinoma, who have not previously received chemotherapy for metastases.
• Cancer of the head and neck. Taxotere ® in combination with cisplatin and 5-fluorouracil